$PTIX News

Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner

Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114

Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market

Results from Phase 1 Multiple-Dose Study of PT00114

Protagenic Therapeutics Reports Topline Phase 1 Safety Data For PT00114, Was Well Tolerated Across All Dose Ranges Studied; Paves Way For Phase 2 In Stress-Related Neuropsychiatric Conditions

Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice

Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study

Protagenic Therapeutics Completes Enrollment, Dosing In Its Multiple Ascending Dose Phase 1 Trial Evaluating PT00114

Protagenic Therapeutics shares are trading lower after the company filed a complaint to rescind its share exchange agreement by which it acquired Phytanix Bio.

Protagenic Therapeutics shares are trading lower after the company filed a complaint to rescind its share exchange agreement by which it acquired Phytanix Bio.

Protagenic Therapeutics Files Complaint To Rescind Share Exchange Agreement By Which Co Acquired Phytanix Bio

Protagenic Therapeutics May Offer And Sell Shares Of Common Stock Of Up To $1.75M

Protagenic Therapeutics shares are trading higher after the company announced it expects to file its Quarterly Report on Form 10-Q for the period ended June 30, 2025 in the near future, following a delay attributable to the completion of merger-related consolidation of financial statements, including purchase accounting adjustments, pro forma financial information, and related disclosures.

Protagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq Compliance

Protagenic Therapeutics Expects To File Its Quarterly Report On Form 10-Q For The Period Ended June 30, 2025 In The Near Future, Following A Delay Attributable To The Completion Of Merger-Related Consolidation Of Financial Statements, Including Purchase Accounting Adjustments, Pro Forma Financial Information, And Related Disclosures

Protagenic Therapeutics (PTIX) Shares Surge On Clinical Trial Progress

Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders

Protagenic Therapeutics shares are trading higher after the company announced it has completed the first dose injections in its Phase 1 multiple-dose study of PT00114.

Protagenic Completes First Dose Injections In Phase I Multiple-Dose Study Of PT00114; Topline Safety Data Expected By September; Phase 2 Launch Targeted For Q1 2026

Protagenic Therapeutics Announces Major Restructuring: Transitions To Virtual Operating Model, Cuts $8M In Annual Costs, Halts Preclinical Programs, Terminates CEO And COO, Changes Fiscal Year-End, And Refocuses On Lead Clinical Trial For PT00114